Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Glioma therapy up-date].

B Pilo de la Fuente1, J Dalmau, M Rosenfeld

  • 1Servicio de Neurología, Hospital Ramón y Cajal, Madrid, Spain.

Neurologia (Barcelona, Spain)
|March 17, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiation-Induced Wavelength Shifts in Fiber Bragg Gratings Exposed to Gamma Rays and Neutrons in a Nuclear Reactor.

Sensors (Basel, Switzerland)·2025
Same author

Predicting the future of autoimmune encephalitides.

Revue neurologique·2024
Same author

Eponyms related to oculosympathetic paresis, the apraclonidine test and the comeback of Pourfour du Petit.

Journal francais d'ophtalmologie·2022
Same author

Pediatric lung function testing during a pandemic: An international perspective.

Paediatric respiratory reviews·2020
Same author

The role of infections in autoimmune encephalitides.

Revue neurologique·2019
Same author

Iceberg sign as a dermoscopic clue of actinic keratosis neglecta.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019

Temozolomide improves survival for malignant brain tumors, particularly glioblastoma multiforme, when combined with radiation therapy. Its effectiveness is enhanced in tumors with a methylated MGMT gene promoter, reducing DNA repair.

Area of Science:

  • Oncology
  • Neuro-oncology
  • Pharmacology

Background:

  • Malignant brain tumors historically have a poor prognosis with limited effective chemotherapy options.
  • Temozolomide represents a novel second-generation alkylating agent offering improved efficacy for high-grade gliomas.

Purpose of the Study:

  • To review the diagnosis and treatment of malignant brain tumors.
  • To focus on the role and efficacy of temozolomide in glioma therapy.

Main Methods:

  • Review of existing literature on malignant brain tumor treatment.
  • Analysis of temozolomide's pharmacokinetic and pharmacodynamic properties.
  • Evaluation of clinical trial data on temozolomide in combination with radiation therapy.

Main Results:

Related Experiment Videos

  • Temozolomide is generally well-tolerated with favorable drug properties.
  • Concurrent and adjuvant temozolomide with radiation significantly improves overall survival in newly diagnosed glioblastoma multiforme.
  • Patient benefit is greatest in those with methylated O6-methyl-guanine DNA methyl transferase (MGMT) gene promoter, indicating reduced DNA repair capacity.

Conclusions:

  • Temozolomide is a valuable chemotherapeutic agent for malignant gliomas.
  • Combination therapy with radiation offers a survival benefit, especially in MGMT-methylated tumors.
  • Further research into temozolomide's role in brain tumor treatment is warranted.